Beijing Scitop Bio-tech Co (300858) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached ¥77.61 million, up 31.49% year-over-year, driven by growth in probiotic and microecological product lines.

• Net profit attributable to shareholders was ¥20.33 million, a 9.79% increase compared to the same quarter last year.

• Cash flow from operating activities turned negative at -¥0.53 million, mainly due to reduced receivables collection and increased procurement spending.

Financial highlights

• Gross margin improved as revenue growth outpaced cost increases, with operating income at ¥25.33 million.

• Basic and diluted EPS both rose to ¥0.08 from ¥0.07 year-over-year.

• Total assets at quarter-end were ¥1.93 billion, up 0.86% from year-end 2024.

• Non-recurring gains totaled ¥3.66 million, mainly from government grants and tax rebates.

Outlook and guidance

• Board approved adjustments to the scale and structure of the food R&D and production base project, with surplus funds of ¥62.58 million to be permanently added to working capital, pending shareholder approval.

• Project completion date extended to December 31, 2026.